MRI Assessment of Leukemia Response to Therapy
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 8 - 75 |
| Updated: | 5/10/2017 |
| Start Date: | May 2012 |
| End Date: | June 2017 |
| Contact: | Aneela Afzal |
| Email: | afzal@ohsu.edu |
Quantitative DCE-MRI as a Predictor of Therapeutic Response in Acute Leukemia
The purpose of this study is to investigate if a type of magnetic resonance imaging (MRI)
scan of the bone marrow before the start of standard chemotherapy can predict complete
remission of leukemia patients after the therapy. This type of MRI scan, called dynamic
contrast-enhanced MRI (DCE-MRI), measures bone marrow blood flow. For those patients who do
not achieve complete remission status after initial therapy and will be treated with
additional therapy, the investigators are also interested in determining if the second MRI
exam before the additional therapy can predict complete remission. If successfully tested,
the MRI exam may be used in the future to help with early identification of patients who are
unlikely to respond to standard chemotherapy. This will allow for a personalized therapeutic
plan to be developed for these patients at an early stage and prevent them from being
exposed to toxic and ineffective therapies.
scan of the bone marrow before the start of standard chemotherapy can predict complete
remission of leukemia patients after the therapy. This type of MRI scan, called dynamic
contrast-enhanced MRI (DCE-MRI), measures bone marrow blood flow. For those patients who do
not achieve complete remission status after initial therapy and will be treated with
additional therapy, the investigators are also interested in determining if the second MRI
exam before the additional therapy can predict complete remission. If successfully tested,
the MRI exam may be used in the future to help with early identification of patients who are
unlikely to respond to standard chemotherapy. This will allow for a personalized therapeutic
plan to be developed for these patients at an early stage and prevent them from being
exposed to toxic and ineffective therapies.
Inclusion Criteria:
- Newly diagnosed or relapsed AML patients, who are scheduled to receive standard
induction therapy.
- Age > 8 years and requiring no sedation.
- Patients must not be pregnant
- Women of childbearing potential must have negative serum pregnancy test performed
within 7-days prior to start of study
- The subject or subject's legal guardian has the ability to understand and the
willingness to sign a written informed consent and/or assent document. A signed
study-specific informed consent and/or assent must be obtained prior to any study
specific procedures.
Exclusion Criteria:
- Patients who would be normally excluded from undergoing an MRI examination - patients
with a pacemaker, aneurysm clip or any other condition that would warrant avoidance
of a strong magnetic field.
- Patients who have known or suspected allergy to gadolinium-based contrast agent.
- Severe claustrophobia precluding subject from undergoing a MRI
- Patients with acute or chronic kidney dysfunction (estimated Glomerular Filtration
Rate (eGFR) < 30ml/min/1.73 m2 as calculated using the Modification of Diet in Renal
Disease (MDRD) Equation)
- Pregnant women are excluded from this study because of possible risk to the fetus.
We found this trial at
1
site
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Principal Investigator: Wei Huang, PhD
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
